• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Avalglucosidase Alfa (Nexviazyme™) approved by Health Canada

Avalglucosidase Alfa (Nexviazyme™) approved by Health Canada

by CAP | Nov 15, 2021 | News

Health Canada has approved avalglucosidase alfa (Nexviazyme™) for the long-term treatment of late-onset Pompe disease in patients over the age of 6 months.

Recent Posts

  • International Pompe Day 2022
  • Julie
  • Brad
  • Rare Disease Day 2022
  • Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy
  • Terms
  • Privacy

Copyright © 2006 - 2023 Canadian Association of Pompe